Q4 25 EPS
$-0.97
MISS 23.10%
Est. $-0.79
Q4 25 Revenue
$2.9M
MISS 80.61%
Est. $14.8M
vs S&P Since Q4 25
+23.6%
BEATING MARKET
KYMR +33.2% vs S&P +9.6%
Full Year 2025 Results
FY 25 EPS
$-3.69
MISS 6.46%
Est. $-3.47
FY 25 Revenue
$39.2M
MISS 26.90%
Est. $53.6M
Market Reaction
Did KYMR Beat Earnings? Q4 2025 Results
Kymera Therapeutics delivered a sharply disappointing fourth quarter, posting a loss of $0.97 per share against a consensus estimate of $0.79, a miss of 22.78%, while revenue collapsed 61.2% year-over-year to just $2.87 million, falling well short of… Read more Kymera Therapeutics delivered a sharply disappointing fourth quarter, posting a loss of $0.97 per share against a consensus estimate of $0.79, a miss of 22.78%, while revenue collapsed 61.2% year-over-year to just $2.87 million, falling well short of the $17.30 million analysts had anticipated. The primary culprit was a steep decline in collaboration revenue as the company's revenue mix shifted away from its Sanofi partnership toward the newer Gilead Sciences arrangement, compounding the shortfall as R&D expenses climbed to $83.83 million in the quarter from $71.82 million a year earlier, reflecting accelerating investment in its STAT6 degrader program KT-621. The losses, however, are being framed by management as the cost of building a high-conviction clinical pipeline, and a $692 million equity offering completed in December leaves Kymera with roughly $1.62 billion in cash, extending its runway into 2029. Key catalysts ahead include Phase 2b data from the KT-621 atopic dermatitis trial by mid-2027, asthma data in late 2027, and first-in-human Phase 1 results for IRF5 degrader KT-579 in the second half of 2026, milestones that analysts broadly view as the true test of the company's valuation thesis.
Key Takeaways
- • Increased R&D investment in STAT6 program, platform and discovery programs
- • Collaboration revenue from Gilead Sciences in Q4 2025 replacing prior Sanofi-driven revenue
- • Completion of $692 million equity offering bolstering cash position to $1.6 billion
KYMR YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
KYMR Revenue by Segment
With YoY comparisons, source: SEC Filings
“We set a high bar for what we wanted to achieve in 2025 and exceeded expectations. We enter this year with momentum and focus as we continue to advance an innovative and robust pipeline, anchored by our STAT6 program.”
— Nello Mainolfi, Q4 2025 Earnings Press Release
KYMR Earnings Trends
KYMR vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
KYMR EPS Trend
Earnings per share: estimate vs actual
KYMR Revenue Trend
Quarterly revenue: estimate vs actual
KYMR Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.85 | $-0.71 | +16.07% | $34.4M | +317.57% |
| Q4 25 MISS FY | $-0.79 | $-0.97 | -23.10% | $2.9M | -80.61% |
| FY Full Year | $-3.47 | $-3.69 | -6.46% | $39.2M | -26.90% |
| Q3 25 MISS | $-0.79 | $-0.94 | -19.50% | $2.8M | -88.06% |
| Q2 25 MISS | $-0.80 | $-0.95 | -19.12% | $11.5M | -52.51% |
| Q1 25 BEAT | $-0.91 | $-0.82 | +9.90% | $22.1M | +105.88% |